Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 7, 2025
Hepatocellular
carcinoma
(HCC),
accounting
for
90%
of
primary
liver
cancers,
is
a
high-mortality
malignancy
and
the
third
leading
cause
cancer-related
deaths
globally,
with
major
risk
factors
like
hepatitis
B/C,
aflatoxin
exposure,
obesity.
Most
patients
are
diagnosed
at
advanced
stages,
5-year
survival
rate
below
10%.
Therefore,
HCC
treatment
research
still
face
significant
challenges,
more
effective
treatments
need
to
be
further
explored.
We
searched
PubMed,
Scopus,
Web
Science
Embase
from
time
repository
construction
March
1,
2025,
preliminary
included
studies
involving
animal
experiments
on
therapeutic
effects
Chimeric
Antigen
Receptor
T-cell
(CAR-T
cell)
therapy
HCC.
After
exclusion
evaluation
literature,
random/fixed
model
was
employed
perform
meta-analysis
obtain
Weighted
Mean
Difference
(WMD)
95%
confidence
interval
(CI)
tumor
volume
mass.
then
verify
robustness
results
through
subgroup
analysis
sensitivity
analysis.
Use
Q-test
evaluate
heterogeneity
quantify
it
based
I²
value.
total
16
studies.
Multiple
independent
sets
data
were
extracted
these
studies,
which
25
used
volume-based
mass-based
meta-analysis.
Regarding
volume,
The
combined
mean
CAR-T
group/control
group
resulted
in
an
WMD
-515.77
(95%
CI:
-634.78
-396.76;
=90.8%).
Meanwhile,
mass,
-0.30
-0.38
-0.22;
=
94.4%).
bias
validated
reliability
conclusions.
Based
dual-index
meta-analysis,
have
been
proved
possess
effect
However,
funnel
plot
mass
Egger's
regression
suggest
potential
presence
publication
bias.
Thus,
warrants
alone
or
as
adjuvant
treatment.
Язык: Английский
Unraveling Glypican-3: From Structural to Pathophysiological Roles and Mechanisms—An Integrative Perspective
Cells,
Год журнала:
2025,
Номер
14(10), С. 726 - 726
Опубликована: Май 15, 2025
Glypican3
(GPC3),
initially
cloned
from
rats
40
years
ago,
deeply
participates
in
the
development
and
homeostasis
of
multiple
tissues
organs.
Dysregulation
GPC3
is
associated
with
cancerous
noncancerous
diseases.
Loss
function
leads
to
Simpson-Golabi-Behmel
syndrome
(SGBS),
which
characterized
by
pre-
postnatal
overgrowth.
However,
exerts
both
promotive
inhibitory
roles
cancer
development.
Recent
studies
suggest
that
dual
may
be
attributed
its
structural
features.
This
review
comprehensively
summarizes
features,
pathophysiological
functions,
underlying
mechanism
finally
discuss
relationship
between
modification
aiming
provide
a
theoretical
basis
for
novel
therapeutic
strategies
targeting
treat
diseases
including
cancer.
Язык: Английский